I got in early on pcyc, single digits, and truly believe that it is a two-part equation between management and the therapy itself. That's why I nibbled on MDGN. CEO's experience speaks for itself, so now my question become... is that the best they can do regarding raising money? Why not partner? PCYC first raised money under their CEO at .93 cents, above where it was currently trading. Then they did a dutch offering, and the CEO participated with each raise. Can anyone explain this? See the huge market for Hep C, but about to drop this stock... LAME OFFERING, warrents at less than 7??
brotherlu2003, you ask why Medgenics cannot partner. It may not answer your question, but have a look at the following:
Medgenics first mentioned it was in active discussions with major potential strategic partners in February 2009, yes over 4 years ago.
This was expanded upon in the 2008 annual report to state: "The Company’s active discussions with major potential strategic partners have expanded since the initial announcement in February 2009, with additional companies having expressed interest in one or more therapeutic applications. Further updates on these discussions will be made in due course."
In the 2009 annual report, it was said that "The Company’s active discussions with potential strategic partners have expanded with additional companies expressing interest in one or more therapeutic applications. Furthermore, as the Company has developed its model for Biopump regional processing centres, this model has sparked new interest in the Biopump as a technology platform, particularly in potential partners with expertise in manufacturing and in medical devices. Further updates on these discussions will be given in due course."
The only collaboration that Medgenics have announced is the failed Baxter collaboration with no formal explanation given as to why this was dropped several years ago. Other than that, nada, not a public sniff of a deal.
So yes, you are right to ask why not. Despite EPODURE's success, has there really been NO pharma willing to offer Medgenics a deal that would not be better than the massive dilution and warrants of the last two fundraisings??
Most deals come when companies are further into the Phase trials, altho not always....Barrer took over recently - let's see as the year unfolds what develops.. Yes, this was the best they could do for now, financing-wise. But I've seen many biotechs raise money at3 or 4 dollars, only to be 15 or 18 later in the year. When you're biotech in need of money and not advanced in trials that far, you're at the mercy of the Street. With Blech, Barrer, the results so far, the technolgy, the 30mm in cash and the ridiculously low mkt cap, I think it's a fairly safe play here, with excellent opportunity